Molecular Basis of Epigenetic Regulation in Cancer Diagnosis and Treatment

Overview

Journal Front Genet

Date 2022 Sep 12

PMID 36092905

Authors

Sonam Tulsyan

Mehreen Aftab

Sandeep Sisodiya

Asiya Khan

Atul Chikara

Pranay Tanwar

Showket Hussain

Affiliations

Soon will be listed here.

Abstract

The global cancer cases and mortality rates are increasing and demand efficient biomarkers for accurate screening, detection, diagnosis, and prognosis. Recent studies have demonstrated that variations in epigenetic mechanisms like aberrant promoter methylation, altered histone modification and mutations in ATP-dependent chromatin remodelling complexes play an important role in the development of carcinogenic events. However, the influence of other epigenetic alterations in various cancers was confirmed with evolving research and the emergence of high throughput technologies. Therefore, alterations in epigenetic marks may have clinical utility as potential biomarkers for early cancer detection and diagnosis. In this review, an outline of the key epigenetic mechanism(s), and their deregulation in cancer etiology have been discussed to decipher the future prospects in cancer therapeutics including precision medicine. Also, this review attempts to highlight the gaps in epigenetic drug development with emphasis on integrative analysis of epigenetic biomarkers to establish minimally non-invasive biomarkers with clinical applications.

Citing Articles

Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review.

Tao W, Sun Q, Xu B, Wang R Life (Basel). 2025; 15(2).

PMID: 40003691 PMC: 11856636. DOI: 10.3390/life15020283.

Promoter Hypermethylation of the BRCA1 Gene as a Novel Biomarker for Prostate Cancer.

Saleem M, Mustafa M Cureus. 2024; 16(8):e66467.

PMID: 39246954 PMC: 11380563. DOI: 10.7759/cureus.66467.

Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies.

Wang Y, Qin J, Sharma A, Dakal T, Wang J, Pan T Cancer Cell Int. 2024; 24(1):305.

PMID: 39227952 PMC: 11373255. DOI: 10.1186/s12935-024-03487-y.

Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression.

Wang D, Zhang Y, Li Q, Li Y, Li W, Zhang A Genes Dis. 2024; 11(5):101020.

PMID: 38988323 PMC: 11233905. DOI: 10.1016/j.gendis.2023.04.040.

A DNA Methylation Signature From Buccal Swabs to Identify Tuberculosis Infection.

Karlsson L, Ohrnberg I, Sayyab S, Martinez-Enguita D, Gustafsson M, Espinoza P J Infect Dis. 2024; 231(1):e47-e58.

PMID: 38962817 PMC: 11793033. DOI: 10.1093/infdis/jiae333.

References

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Metere A, Graves C . Factors Influencing Epigenetic Mechanisms: Is There A Role for Bariatric Surgery?. High Throughput. 2020; 9(1). PMC: 7151212. DOI: 10.3390/ht9010006. View

Lorincz A . The Promise and the Problems of Epigenetics Biomarkers in Cancer. Expert Opin Med Diagn. 2011; 5(5):375-379. PMC: 3191528. DOI: 10.1517/17530059.2011.590129. View

Durand X, Moutereau S, Xylinas E, De La Taille A . Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn. 2011; 11(2):137-44. DOI: 10.1586/erm.10.122. View

Jones A, Teschendorff A, Li Q, Hayward J, Kannan A, Mould T . Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med. 2013; 10(11):e1001551. PMC: 3825654. DOI: 10.1371/journal.pmed.1001551. View

Sarno F, Benincasa G, List M, Barabasi A, Baumbach J, Ciardiello F . Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. Clin Epigenetics. 2021; 13(1):66. PMC: 8010949. DOI: 10.1186/s13148-021-01047-z. View

Ramon L, David C, Fontaine K, Lallet E, Marcaillou C, Martin-Lanneree S . Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens. Biomark Insights. 2018; 13:1177271918763357. PMC: 5858679. DOI: 10.1177/1177271918763357. View

Silverman E, Schmidt H, Anastasiadou E, Altucci L, Angelini M, Badimon L . Molecular networks in Network Medicine: Development and applications. Wiley Interdiscip Rev Syst Biol Med. 2020; 12(6):e1489. PMC: 7955589. DOI: 10.1002/wsbm.1489. View

Li X, Cheung K, Ma X, Tian L, Zhao J, Go M . Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene. 2011; 31(29):3419-30. DOI: 10.1038/onc.2011.511. View

10.

Salam I, Hussain S, Mir M, Dar N, Abdullah S, Siddiqi M . Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: a high-risk area. Mol Cell Biochem. 2009; 332(1-2):51-8. DOI: 10.1007/s11010-009-0173-7. View

11.

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

12.

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

13.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

14.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

15.

Ganesan A, Arimondo P, Rots M, Jeronimo C, Berdasco M . The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics. 2019; 11(1):174. PMC: 6888921. DOI: 10.1186/s13148-019-0776-0. View

16.

Bao X, Anastasov N, Wang Y, Rosemann M . A novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med. 2019; 17(1):380. PMC: 6889649. DOI: 10.1186/s12967-019-2126-6. View

17.

Tost J . DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Methods Mol Biol. 2008; 507:3-20. DOI: 10.1007/978-1-59745-522-0_1. View

18.

Li M, Shi M, Xu Y, Qiu J, Lv Q . Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer. Cell Transplant. 2021; 30:9636897211027521. PMC: 8554562. DOI: 10.1177/09636897211027521. View

19.

Sinha R, Hussain S, Mehrotra R, Kumar R, Kumar K, Pande P . Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One. 2013; 8(4):e60142. PMC: 3616004. DOI: 10.1371/journal.pone.0060142. View

20.

Lamb Y, Dhillon S . Epi proColon 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol Diagn Ther. 2017; 21(2):225-232. DOI: 10.1007/s40291-017-0259-y. View